Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.

Endocrinol Metab (Seoul) · 2020 · PMC7386128 · PMID 32615717

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

Similar patterns were observed, and the empagliflozin add-on therapy demonstrated superior efficacy compared with the sulfonylurea dose-increasing strategy with borderline significance ( Supplemental Table S1 ).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.